Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Gas Research
Published in: Medical Gas Research 1/2013

Open Access 01-12-2013 | Review

Bustling argon: biological effect

Authors: Zhouheng Ye, Rongjia Zhang, Xuejun Sun

Published in: Medical Gas Research | Issue 1/2013

Login to get access

Abstract

Argon is a noble gas in group 18 of the periodic table. Certificated to exist in air atmosphere merely one century ago, discovery of argon shows interesting stories of researching and exploring. It was assumed to have no chemical activity. However, argon indeed present its biological effect on mammals. Narcotic effect of argon in diving operation and neur-protective function of argon in cerebral injury demonstrate that argon has crucial effect and be concentrated on is necessary. Furthermore, consider to be harmless to human, argon clinical application in therapy would be another option.
Literature
1.
Haynes WM, et al: CRC handbook of chemistry and physics. 1986, 2656-ISBN 1-4398-5511-0, 92
2.
Rayleigh L, Ramsay W: Argon, a new constituent of the atmosphere. Proceedings of the Royal Society of London. 1894, 57: 265-287. 10.1098/rspl.1894.0149.CrossRef
3.
Soldatov PE, D’Iachenko AI, Pavlov BN, Fedotov AP, Chuguev AP: Survival of laboratory animals in argon-containing hypoxic gaseous environments. Aviakosm Ekolog Med. 1998, 32: 33-37.PubMed
4.
Pavlov B, Buravkov S, Soldatov P, Vdovin A, Deviatova N: The effects of oxygen-argon gaseous mixtures on humans under long-term hyperbaric condition. 1999, Heidelberg: Springer, 561-564.
5.
Yarin YM, Amarjargal N, Fuchs J, et al: Argon protects hypoxia-, cisplatin- and gentamycin-exposed hair cells in the newborn rat’s organ of Corti. Hear Res. 2005, 201: 1-9. 10.1016/j.heares.2004.09.015.PubMedCrossRef
6.
Loetscher PD, Rossaint J, Rossaint R, et al: Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care. 2009, 13: R206-10.1186/cc8214.PubMedCentralPubMedCrossRef
7.
Ryang YM, Fahlenkamp AV, Rossaint R, et al: Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats. Crit Care Med. 2011, 39: 1448-1453. 10.1097/CCM.0b013e31821209be.PubMedCrossRef
8.
Levy DI, Sucher NJ, Lipton SA: Redox modulation of NMDA receptor-mediated toxicity in mammalian central neurons. Neurosci Lett. 1990, 110: 291-296. 10.1016/0304-3940(90)90862-4.PubMedCrossRef
9.
David HN, Haelewyn B, Degoulet M, Colomb DG, Risso JJ, Abraini JH: Ex vivo and in vivo neuroprotection induced by argon when given after an excitotoxic or ischemic insult. PLoS One. 2012, 7: e30934-10.1371/journal.pone.0030934.PubMedCentralPubMedCrossRef
10.
Brucken A, Cizen A, Fera C, et al: Argon reduces neurohistopathological damage and preserves functional recovery after cardiac arrest in rats. Br J Anaesth. 2013, 110 (suppl 1): i106-i112. 10.1093/bja/aes509.PubMedCrossRef
11.
Zhuang L, Yang T, Zhao H, et al: The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. Crit Care Med. 2012, 40: 1724-1730. 10.1097/CCM.0b013e3182452164.PubMedCrossRef
12.
Abraini JH, Kriem B, Balon N, Rostain JC, Risso JJ: Gamma-aminobutyric acid neuropharmacological investigations on narcosis produced by nitrogen, argon, or nitrous oxide. Anesth Analg. 2003, 96: 746-749. Table of contentsPubMedCrossRef
13.
Wirkner K, Kofalvi A, Fischer W, et al: Supersensitivity of P2X receptors in cerebrocortical cell cultures after in vitro ischemia. J Neurochem. 2005, 95: 1421-1437. 10.1111/j.1471-4159.2005.03465.x.PubMedCrossRef
14.
Seto T, Isogai H, Ozaki M, Nosaka S: Noble gas binding to human serum albumin using docking simulation: nonimmobilizers and anesthetics bind to different sites. Anesth Analg. 2008, 107: 1223-1228. 10.1213/ane.0b013e31817f1317.PubMedCrossRef
15.
Rostain JC, Lavoute C, Risso JJ, Vallee N, Weiss M: A review of recent neurochemical data on inert gas narcosis. Undersea Hyperb Med. 2011, 38: 49-59.PubMed
16.
Chen S, Guo SX, Hong Y, Zhang JM: Advances in research on neuroprotective effects of inert gas. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2011, 40: 101-106.PubMed
17.
Fahlenkamp AV, Rossaint R, Haase H, et al: The noble gas argon modifies extracellular signal-regulated kinase 1/2 signaling in neurons and glial cells. Eur J Pharmacol. 2012, 674: 104-111. 10.1016/j.ejphar.2011.10.045.PubMedCrossRef
18.
Pagel PS, Krolikowski JG, Shim YH, et al: Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg. 2007, 105: 562-569. 10.1213/01.ane.0000278083.31991.36.PubMedCrossRef
19.
Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood). 2010, 235: 886-891. 10.1258/ebm.2010.009366.CrossRef
Metadata
Title
Bustling argon: biological effect
Authors
Zhouheng Ye
Rongjia Zhang
Xuejun Sun
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Medical Gas Research / Issue 1/2013
Electronic ISSN: 2045-9912
DOI
https://doi.org/10.1186/2045-9912-3-22

Other articles of this Issue 1/2013

Medical Gas Research 1/2013 Go to the issue

Review

The immunomodulatory role of carbon monoxide during transplantation

Commentary

The summer of hydrogen sulfide: highlights from two international conferences

Research

Hydrogen-rich saline ameliorates the retina against light-induced damage in rats

Commentary

Hypocapnia as a poor prognostic factor in aneurysmal subarachnoid hemorrhage

Review

Hydrogen sulfide as a vasculoprotective factor

Review

Hypercapnia: is it protective in lung injury?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits